Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Curis ( (CRIS) ).
On January 7, 2026, Curis entered into a private placement securities purchase agreement with healthcare-focused institutional investors and company insiders for a PIPE financing structured around 20,195 shares of Series B convertible non-redeemable preferred stock bundled with three tranches of warrants, priced at $1,000 per unit and exercisable at $0.75 per share, which together could yield up to approximately $80.8 million in gross proceeds if all warrants are exercised, including about $20.2 million expected at closing on or about January 8, 2026. The complex preferred and warrant package is designed to convert into common stock following shareholder approval and is accompanied by registration rights for resale, while Curis plans to use the initial proceeds, alongside existing cash, to fund research and development and general corporate purposes, extend its cash runway into 2027, support its strategic pivot toward emavusertib combination trials in chronic lymphocytic leukemia and primary CNS lymphoma, and bolster stockholders’ equity as it seeks to maintain compliance with Nasdaq Capital Market listing standards after prior delisting warnings tied to market value and equity thresholds.
The most recent analyst rating on (CRIS) stock is a Hold with a $0.82 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.
Spark’s Take on CRIS Stock
According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.
The score is held down primarily by weak financial durability (negative equity, rising debt, and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD and very low RSI/Stoch). Offsetting factors include encouraging clinical/program progress and improved losses discussed on the earnings call, plus a modest balance-sheet benefit from the Erivedge sale, but these do not fully counter near-term funding and listing risks.
To see Spark’s full report on CRIS stock, click here.
More about Curis
Curis, Inc., based in Lexington, Massachusetts, is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small-molecule inhibitor of IRAK4 and FLT3. Its lead asset is being evaluated in the TakeAim Lymphoma Phase 1/2 study in combination with BTK inhibitor ibrutinib for relapsed or refractory primary central nervous system lymphoma and in a Phase 2 study in combination with an approved Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia; prior monotherapy and combination studies in acute myeloid leukemia have been completed, and with additional resources the company plans to continue emavusertib development in AML, where the drug holds U.S. and EU orphan-drug designations in several hematologic indications.
Average Trading Volume: 348,560
Technical Sentiment Signal: Sell
Current Market Cap: $12.93M
See more data about CRIS stock on TipRanks’ Stock Analysis page.